As we have discussed throughout January, Candida antarctica lipase A (CALA) is a powerful biocatalyst. However, in industry, Candida antarctica lipase B (CALB) is the money maker while our January Enzyme of the Month CALA remains more in the lab. Here's why:
?? ???????????????????? ???????????????????????? & ?????????????????? ???? ??????????: CALB has been commercialized for decades, and suppliers have optimized production, supply chains, and cost efficiency. Large-scale fermentation and purification processes for CALB are well-optimized, making it cost-effective. Since fewer companies manufacture CALA, it is less widely available and more expensive for industrial applications.
?? ???????????? ?????????????????????? & ??????????????????????: CALB has a well-defined substrate selectivity, favoring secondary alcohols and esters with high efficiency, making it useful in pharmaceuticals, flavors & fragrances, and biodiesel.
While CALA has broader substrate scope, its lower activity and lower selectivity for industrially relevant reactions make it less desirable in specific applications.
?? ???????????????????????????? & ??????????????????????: CALB is easier to immobilize on traditional carriers, making it ideal for repeated batch processes or continuous flow reactions. CALA does not immobilize as efficiently, making it less desirable for industrial reusability. Cascade's tunable immobilization platform solves this problem.
?
?? ???????????????? ??????????????????????????????:?Because CALB has been used extensively for decades, many industrial processes and patents reference CALB-specific conditions. Switching to another enzyme, such as CALA, would require costly process re-optimization, re-validation, and regulatory updates. This creates a lock-in effect, where industries continue using CALB because it is already validated and proven.
While CALA has some unique properties, CALB dominates the industry due to its commercial availability, performance, immobilization, and lower risk in process development. Once an enzyme becomes widely used, it benefits from economies of scale and industry standardization, reinforcing its dominance over potential alternatives like CALA. However, scalable immobilization platforms like the one we are building at Cascade will make it easier to onboard new enzymes with better performance for specific transformations.